Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics
暂无分享,去创建一个
G. Gregoriadis | B. McCormack | G. Gregoriadis | A. Fernandes | M. Mital | B. McCormack | A. Fernandes | M. Mital | Gregory Gregoriadis | Ana I. Fernandes
[1] C Delgado,et al. The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.
[2] O. Nishimura,et al. Lipid on capsular polysaccharides of gram-negative bacteria. , 1981, The Journal of biological chemistry.
[3] M. Papisov,et al. Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility , 1994 .
[4] F. Kuypers,et al. Erythrocyte defense against hydrogen peroxide: preeminent importance of catalase. , 1991, The Journal of laboratory and clinical medicine.
[5] J. Uren,et al. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides. , 1979, Cancer research.
[6] M. Laguerre,et al. Erythrocytes as Carriers for L‐Asparaginase. Methodological and Mouse In‐vivo Studies , 1990, The Journal of pharmacy and pharmacology.
[7] G. Gregoriadis,et al. Polysialic acids: potential in drug delivery , 1993, FEBS letters.
[8] C. Wiblin,et al. The effect of chemical modification of L-asparaginase on its persistence in circulating blood of animals. , 1979, Biochemical pharmacology.
[9] J. Finne. Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. , 1982, The Journal of biological chemistry.
[10] L. Pelliniemi,et al. The Polysialic Acid Units of the Neural Cell Adhesion Molecule N-CAM Form Filament Bundle Networks* , 1998, The Journal of Biological Chemistry.
[11] V. Bocci. Metabolism of protein anticancer agents. , 1987, Pharmacology & therapeutics.
[12] M. Keating,et al. L-asparaginase and PEG asparaginase--past, present, and future. , 1993, Leukemia & lymphoma.
[13] M. Nucci,et al. The therapeutic value of poly(ethylene glycol)-modified proteins , 1991 .
[14] G. Gregoriadis,et al. Polysialylated asparaginase: preparation, activity and pharmacokinetics. , 1997, Biochimica et biophysica acta.
[15] R. Mandrell,et al. Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants. , 1982, Journal of immunology.
[16] M. Lifely,et al. Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide , 1985, Infection and immunity.
[17] G. Gregoriadis,et al. Synthesis, characterization and properties of sialylated catalase. , 1996, Biochimica et biophysica acta.
[18] G. Gregoriadis,et al. Tumour regression with liposome-entrapped asparaginase: some immunological advantages. , 1976, Biochemical Society transactions.